Residual disease-guided strategy combining ibrutinib and venetoclax for the treatment of relapsed or refractory chronic lymphocytic leukemia

被引：0
|
作者：
Stocker, Nicolas
机构：
来源：
HEMATOLOGIE | 2022年 / 28卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [41] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    Shustik, C.
    Bence-Bruckler, I.
    Delage, R.
    Owen, C. J.
    Toze, C. L.
    Coutre, S.
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1185 - 1196
  • [42] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    C. Shustik
    I. Bence-Bruckler
    R. Delage
    C. J. Owen
    C. L. Toze
    S. Coutre
    Annals of Hematology, 2017, 96 : 1185 - 1196
  • [43] Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
    Waldron, Madeline
    Winter, Allison
    Hill, Brian T.
    CLINICAL PHARMACOKINETICS, 2017, 56 (11) : 1255 - 1266
  • [44] Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax
    Madeline Waldron
    Allison Winter
    Brian T. Hill
    Clinical Pharmacokinetics, 2017, 56 : 1255 - 1266
  • [45] Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review
    Sugianto, Jeremy Octavian
    Purushotama, Nyoman Bagus Satcitta Ananda
    Ontowirjo, Yudi Ali Putra
    Sutanto, Mario
    Kurniawan, Andree
    ANNALS OF ONCOLOGY, 2023, 34 : S1447 - S1447
  • [46] Combination of ibrutinib and venetoclax in first-line treatment of chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (01): : 12 - 13
  • [47] Venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia
    Yang, Lin
    Banerji, Versha
    LANCET ONCOLOGY, 2024, 25 (04): : 413 - 414
  • [48] Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
    Handunnetti, Sasanka
    Anderson, Mary Ann
    Roberts, Andrew W.
    Davids, Matthew S.
    Ma, Shuo
    Boyer, Michelle
    Arzt, Jennifer
    Al Masud, Abdullah
    Popovic, Relja
    Jacobson, Amanda
    Kim, Su Y.
    Seymour, John F.
    EJHAEM, 2021, 2 (02): : 266 - 271
  • [49] Outcomes of Ibrutinib Therapy Given after Prior Venetoclax Therapy in Ibrutinib-Naive Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
    Brown, Jennifer R.
    Davids, Matthew S.
    Chang, Julie
    Ma, Shuo
    Biondo, Juliana
    Mobasher, Mehrdad
    Mun, Yong
    Mato, Anthony R.
    BLOOD, 2018, 132
  • [50] COST-EFFECTIVENESS OF IBRUTINIB AND RITUXIMAB FOR THE RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN CHINA
    Yang, F.
    Kumar, A.
    Rojanasarot, S.
    Schommer, J. C.
    Shao, R.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
12345